BackCatabasis Pharmaceuticals Overview

Catabasis Pharmaceuticals Long Term Debt

Latest long-term debt for CATB: $3.1M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$3.06M

Peer trimmed avg / median

Loading

Catabasis Pharmaceuticals Long Term Debt History

Loading

Catabasis Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Catabasis Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Catabasis Pharmaceuticals (CATB) FAQ

The latest long-term debt for CATB is $3.1M as of September 2025. Investors often review this figure alongside Catabasis Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

A long-term debt figure of $3.1M for CATB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CATB's long-term debt ($3.1M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Catabasis Pharmaceuticals's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.